pf-04136309
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00689273)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2ANTAGONIST
CCR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-04136309
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02732938 | Phase 2 | May 4, 2016 | Pfizer |
| NCT02598206 | Phase 1 | Dec 1, 2015 | Pfizer |
| NCT01413022 | Phase 1 | Apr 1, 2012 | National Cancer Institute (NCI), Washington University in St. Louis |
| NCT01226797 | Phase 2 | Dec 1, 2010 | Pfizer |
| NCT00689273 | Phase 2 | Aug 1, 2008 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 2 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1